

**The cost effectiveness of nalmefene for reduction of alcohol consumption in alcohol-dependent patients with high or very high drinking-risk levels from a UK societal perspective**

Brodtkorb TH, Bell M, Irving AH, Laramée P.

CNS drugs

2016; 30(2):163-177

**ARTICLE IDENTIFIERS**

DOI: 10.1007/s40263-016-0310-2

PMID: 26879458

PMCID: not available

**JOURNAL IDENTIFIERS**

LCCN: not available

pISSN: 1172-7047

eISSN: 1179-1934

OCLC ID: not available

CONS ID: not available

US National Library of Medicine ID: not available

This article was identified from a query of the SafetyLit database.